1. Home
  2. MIN vs BCYC Comparison

MIN vs BCYC Comparison

Compare MIN & BCYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MFS Intermediate Income Trust

MIN

MFS Intermediate Income Trust

N/A

Current Price

$13.65

Market Cap

261.4M

Sector

Finance

ML Signal

N/A

Logo Bicycle Therapeutics plc

BCYC

Bicycle Therapeutics plc

N/A

Current Price

$2.90

Market Cap

256.5M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
MIN
BCYC
Founded
1988
2009
Country
United States
United Kingdom
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
261.4M
256.5M
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
MIN
BCYC
Price
$13.65
$2.90
Analyst Decision
Buy
Analyst Count
0
9
Target Price
N/A
★ $9.17
AVG Volume (30 Days)
26.0K
★ 402.5K
Earning Date
01-01-0001
10-29-2026
Dividend Yield
★ 7.31%
N/A
EPS Growth
★ N/A
N/A
EPS
★ 0.08
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$172.25
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.27
$3.04
52 Week High
$14.39
$7.83

Technical Indicators

Market Signals
Indicator
MIN
BCYC
Relative Strength Index (RSI) 69.11 29.77
Support Level $2.38 N/A
Resistance Level $14.37 $3.94
Average True Range (ATR) 0.12 0.18
MACD -0.39 -0.07
Stochastic Oscillator 10.71 5.05

Price Performance

Historical Comparison
MIN
BCYC

About MIN MFS Intermediate Income Trust

Aberdeen Intermediate Income Fund is a diversified, closed-end fixed-income management investment company. The fund's investment objective is to seek high current income, but may also consider capital appreciation.

About BCYC Bicycle Therapeutics plc

Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United Kingdom.

Share on Social Networks: